age-related macular degeneration

Algorithm could change way to treat wet AMDAn algorithm for guiding clinical judgments about the futility of anti-VEGF treatment of neovascular age-related macular degeneration (nvAMD) has importance from clinical, ethical, and legal perspectives and would be a valuable decision-making tool for retina specialists and payors, according to David T. Wong, MD.
Investigational wet AMD therapies aim for innovative targetsMany investigational drugs under development for the treatment of neovascular age-related macular degeneration (nvAMD) have advanced into the clinical trial stage, including several that are being evaluated in pivotal trials, said Peter K. Kaiser, MD.
Failed cell therapy study offers positives, raises new questionsPatients with a history of frequent anti-vascular endothelial growth factor (anti-VEGF) injections for the treatment of age-related macular degeneration (AMD) may not be the best potential candidates for encapsulated cell technology (ECT).
Mediterranean diet may protect against macular degeneration
Mediterranean diet may protect against macular degenerationThe Mediterranean diet reduces the risk of age-related macular degeneration (AMD), according to a study of two Portuguese populations.
Google DeepMind searches for signs of retinopathyGoogle is using its DeepMind computing system to search for early signs of diabetic retinopathy and neovascular age-related macular degeneration (nAMD), the company announced this month.
Pipeline for dry AMD features diverse compoundsA number of drugs are being investigated in clinical trials as treatment for slowing the growth of geographic atrophy that is secondary to age-related macular degeneration.
New prevention and monitoring strategies for neovascular AMDNutritional supplements continue to be a viable prevention strategy for neovascular age-related macular degeneration (AMD), said Emily Chew, MD.
Home-monitoring device may advance diagnostics, detection of AMDAn ophthalmologist shares the clinical benefits he has experienced with a home vision-monitoring device for his patients with age-related macular degeneration.
Investigational drug Luminate targets integrin receptorsAnti-integrin therapy is a promising new approach in the treatment of vitreoretinal disease. The first drug in this class, Allegro Ophthalmics’ Luminate, is in Phase 2 clinical trials for several indications, including wet age-related macular degeneration, diabetic macular edema, non-proliferative diabetic retinopathy, and vitreomacular traction.
Misdiagnosing macular degenerationA number of macular conditions either mimic or share characteristic findings of age-related macular degeneration (AMD). These resemblances can result in tough clinical decisions and misdiagnosis. Although genetic testing can be helpful, tests are limited by both their efficacy and accuracy.